254751-08-1

Basic information

• Product Name: Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxo-
• Synonyms: Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxo-;{[2-(2-Methyl-2-propanyl)phenyl]amino}(oxo)acetic acid;2-((2-(Tert-butyl)phenyl)amino)-2-oxoacetic acid
• CAS NO: 254751-08-1
• Molecular Formula: C₁₂H₁₅NO₃
• Molecular Weight: 221.2524
• Mol File: 254751-08-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxo-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxo-(254751-08-1)
• EPA Substance Registry System: Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxo-(254751-08-1)

Safety Data

• Hazardous Substances Data: 254751-08-1(Hazardous Substances Data)

Usage

General Description

Acetic acid, 2-[[2-(1,1-dimethylethyl)phenyl]amino]-2-oxo- is a chemical compound that belongs to the category of acetic acids. It is a yellow to light brown powder with a molecular formula of C12H15NO3 and a molecular weight of 221.25 g/mol. Acetic acid, 2-[[2-(1,1-diMethylethyl)phenyl]aMino]-2-oxo- is commonly used in pharmaceutical research and development, as well as in the production of various drugs and pharmaceutical products. It is also known for its potential medicinal properties and is widely studied for its potential therapeutic uses, particularly in the treatment of various diseases and conditions.

Upstream product

• 959508-79-3 ethyl 2-(2-tert-butylanilino)-2-oxo-acetate 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 483334-60-7 methyl 2-[N-(2-tert-butylphenylamino)]-2-oxoacetate 

Downstream Products

• 254750-82-8 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 

Relevant articles and documents

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE

Provided herein are methods and compositions for treatment of an elevated MELD score or Child-Pugh score or their components by administering a of a caspase inhibitor alone or in combination with current treatments for liver disease.

First-in-class pan caspase inhibitor developed for the treatment of liver disease

A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of α-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.